Viral Vector Market Trends and Projections to 2030

Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) — ResearchAndMarkets.com has published a report titled “Viral Vector Manufacturing Markets and Technologies Through 2030.” The report indicates that the global viral vector manufacturing market is expected to increase from $6.3 billion in 2025 to $18.8 billion by 2030, with a compound annual growth rate (CAGR) of 24.6% during this period.

The rise in gene therapy utilizing viral vectors is reshaping healthcare, resulting in a growing need for Good Manufacturing Practice (GMP) compliant materials. The development of viral vectors entails intricate processes impacting various stages from cell culture to purification. Therefore, increasing the availability of GMP-grade materials is essential for meeting clinical demands.

The report also highlights increased regulatory approvals for viral vector-based treatments over the past five years, covering therapies for cancer and monogenic diseases. Key market drivers include the rising rates of chronic illnesses and a demand for enhanced viral vector production, while challenges include high development costs and production barriers.

Why it matters:

• The growth of the viral vector manufacturing market could influence investment opportunities in biotechnology and pharmaceuticals.
• Increased availability of innovative therapies may improve treatment outcomes for various diseases.

The latest:

• The report analyzes data from previous years and provides forecasts through 2030, shedding light on market trends and technological advancements.